ASCL3

Across TCGA pan-cancer cohorts, ASCL3 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ASCL3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ASCL3 RNA is repressed in tumor relative to normal tissue. In most cancer types ASCL3 is over-expressed in tumor, although a few such as KIRC and HNSC show the opposite, repressed pattern.

KIRC, HNSC, and KIRP are the cancer types where ASCL3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ASCL3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	−0.351	<.001	11	view →
HNSC	All	II,III,IV	−0.861	.002	6	view →
KIRP	Male	II,III,IV	−0.235	.016	4	view →
KICH	All	III,IV	−0.317	.037	2	view →
ESCA	Female	All	+0.120	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ASCL3–KIRC

Open the KIRC breakdown →